CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma or leukemia that has come back or is not responding to standard treatment.
- You are between 18 and 85 years old.
- You are well enough to do most daily activities (ECOG score 0-2).
- Your blood counts (hemoglobin, neutrophils, platelets) are at safe levels, and your heart, lung, liver, and kidney function are stable.
- You have not had CAR T-cell therapy or other genetically modified T-cell treatments before.
- You do not have an active serious infection, uncontrolled heart disease, or other major health problems that would make the trial risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial uses a modified virus to deliver CAR-T cells directly into tumors, aiming to treat B-cell lymphoma that has come back or not responded to other treatments. It may be an option if your lymphoma is CD19-positive and you've tried at least two prior therapies.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hear when a new B-cell Lymphoma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.